| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Department of Internal Medicine and Biocenter Oulu, University of Oulu, PO Box 5000, 90014 Oulu, Finland
(Correspondence should be addressed to M Santaniemi; Email: merja.santaniemi{at}oulu.fi)
Objective: Adiponectin is an adipocytokine known to be decreased in obesity. It functions in glucose and fatty acid metabolism and also has an anti-inflammatory role in microvasculature. We wanted to investigate the role of adiponectin as a biomarker of metabolic syndrome (MS) and see how the plasma adiponectin levels relate to new criteria of MS proposed by the International Diabetes Federation.
Methods: Plasma adiponectin concentrations were measured from total of 1041 Finnish subjects with an ELISA – a novel method planned in our laboratory.
Results: In both the sexes, the plasma adiponectin levels were lower in subjects with MS when compared with subjects with no diagnosis of MS (P< 0.001). Plasma adiponectin levels did not differ between subjects with National Cholesterol Education Program (ATPIII) and International Diabetes Federation-defined MS. Lower adiponectin levels were associated with different components of the MS and there was a trend towards decreasing adiponectin levels with an increasing number of components of MS in both the sexes. Subjects in the lowest adiponectin quartile had a significantly higher probability of having MS (P< 0.001), 4.4-fold in males and 7.5-fold in females, when compared with the corresponding individuals in the highest quartile. The probability increased in every lowering quartile of adiponectin level and was independent of body mass index.
Conclusion: We conclude that adiponectin levels correlate with most of the components of the MS and the metabolic cluster per se.
This article has been cited by other articles:
|
|
 |
|
  M.-J. Barahona, N. Sucunza, E. Resmini, J.-M. Fernandez-Real, W. Ricart, J.-M. Moreno-Navarrete, T. Puig, J. Farrerons, and S. M. Webb Persistent Body Fat Mass and Inflammatory Marker Increases after Long-Term Cure of Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3365 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, S. Chewchuk, C. Lavigne, S. Brule, G. Pilon, V. Houde, A. Xu, A. Marette, and G. Sweeney Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E657 - E664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Rowe, C. S. Choi, L. Neff, W. C. Horne, G. I. Shulman, and R. Baron Increased Energy Expenditure and Insulin Sensitivity in the High Bone Mass {Delta}FosB Transgenic Mice Endocrinology, January 1, 2009; 150(1): 135 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Anderson and J. Borlak Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Paul Chubb, Z. Hyde, O. P Almeida, L. Flicker, P. E Norman, K. Jamrozik, G. J Hankey, and B. B Yeap Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study Eur. J. Endocrinol., June 1, 2008; 158(6): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Imamura, R. Takahashi, R. Murakami, H. Kataoka, X. W. Cheng, Y. Numaguchi, T. Murohara, and K. Okumura The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels Eur. J. Endocrinol., February 1, 2008; 158(2): 189 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, R. Retnakaran, A. Hanley, R. Tungtrongchitr, C. Shaw, and G. Sweeney Total and High Molecular Weight But Not Trimeric or Hexameric Forms of Adiponectin Correlate with Markers of the Metabolic Syndrome and Liver Injury in Thai Subjects J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4313 - 4318. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
